Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1

Status

Terminated 2Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 2

Conditions

Vaginal Atrophy 1Urogenital Abnormalities 1Urinary Tract Infections 1Dysuria 1Dyspareunia 1Breast Neoplasms 1

Interventions

Cyclophosphamide 2067Radiotherapy 1990Cisplatin 1856Carboplatin 1560Gemcitabine 1454Paclitaxel 1320Bevacizumab 1320pembrolizumab 1238Docetaxel 1227Oxaliplatin 1184Capecitabine 1178Fluorouracil 1083Dexamethasone 979Magnetic Resonance Spectroscopy 971Nivolumab 936Rituximab 929Drug Therapy 915Surveys and Questionnaires 899Doxorubicin 845Etoposide 843Radiosurgery 816Blood Specimen Collection 816Irinotecan 784Cytarabine 743fludarabine 726Leucovorin 684Surgical Procedures, Operative 640Lenalidomide 618Biopsy 594fludarabine phosphate 569

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Replens × Clear all
NCT01984138 2026-01-28

REVIVE

The Methodist Hospital Research Institute

Phase 2 Active not recruiting
33 enrolled
Breast

Breast Neoplasms

NCT04493333 2024-11-27

Vaginal Dehydroepiandrosterone (DHEA) in Postmenopausal Breast Cancer Survivors on Aromatase Inhibitors

University of Arkansas

Phase 2 Terminated
8 enrolled 11 charts
Breast

Vaginal Atrophy

NCT03185169 2018-07-26

GSM

Alta Bates Summit Medical Center

Phase EARLY_PHASE1 Terminated
14 enrolled

Dyspareunia, Urinary Tract Infections, Urogenital Abnormalities, Dysuria

Data powered by HemOnc (CC BY 4.0) Colophon âš¡